The requestor is asking:

1. Does your Trust have an electronic prescribing and medicines administration system (ePMA)?

	Please tick one option	
a. Yes (go to Q2)		
b. No (go to Q4)		

2. What is the full name of this ePMA system?

Please specify the system name and supplier

System C EPMA module live only for discharge prescribing EPMA live in intensive care areas with Philip ICCA Non-intensive care areas use paper drug charts

3. Which of the following statements best describes the status the data integration of (i) the system that manages clinical patient notes and records and (ii) the pharmacy dispensing system at your Trust?

Please tick one option for (i) and one option for (ii).		
(i) Clinical patient records (ii) Pharmacy Dispensir / medical notes System (PDS)		
a. Electronic and fully integrated		
b. Electronic and partially integrated		
c. Electronic and not integrated		
d. On paper		N/A

4. Which of the following statements best describes your Trust's overall implementation of the ePMA system?

		Please tick one option
a.	ePMA system is fully implemented (Go to Q5)	
b.	ePMA system is partially implemented and progress is ongoing to complete it (Go to Q5)	
C.	ePMA system has been procured from a named supplier and awaiting implementation (Go to Q5)	
d.	Selection of suppliers and procurement of ePMA system is underway (Go to Q5)	
e.	Awaiting funding (Go to Q17)	
f.	No ePMA systems or plans in place (Go to Q17)	
g.	Other – please specify below	

5. To the best of your knowledge when will an ePMA system be fully implemented at your Trust?

	Month	Year
Estimated date of full implementation	Unknown	2023

6. Which of the following statements best describes the interface between the patient record system and the pharmacy dispensing system?

		Please tick one option
a.	Patient records are electronic and fully integrated with pharmacy dispensing system.	
b.	Patient records are electronic and partially integrated with pharmacy dispensing system.	
C.	Patient records are electronic, but not integrated with the pharmacy dispensing system.	
d.	On paper	

7. What is the name of the pharmacy dispensing system at your Trust?

Please specify the system name and supplier

CareFlow Medicines Management (formally WellSky JAC)

8. Can the Trust export data from these systems and, if so, in which of the following formats?

Please tick all that apply		
(i) Patient records system (ii) Pharmacy Dispens System (PDS)		(ii) Pharmacy Dispensing System (PDS)
axls (Excel)		
bcsv or .txt (Text)		
c. Not possible		

9. In principle are the prescribing systems capable of producing an anonymised report of the number of patients treated *by specific drug treatment* and *by diagnosis* a single report?

	Please tick one option	
a. Yes		
b. No		

10. In the case of drugs with multiple indications, e.g., a drug indicated for rheumatoid arthritis and haematology, does the system record sufficient detail to report on how much is used for each indication?

	Please tick one option	
a. Yes		
b. No		

11. In the case of drugs that are used to treat more than one type of cancer, can the system produce a single report that shows the quantity of drug used for each tumour type?

	Please tick one option	
a. Yes		
b. No		

12. In the case of drugs that are used to treat more than one type of cancer, can the system produce a single report that shows the quantity of drug used for each tumour type by cancer stage?

	Please tick one option	
a. Yes		
b. No		

13. Which, if any, of the following fields can be exported from the ePMA system?

Please indicate yes or no per item		
	Yes	No
a. Date (month year)		
b. Diagnosis or indication		
c. Drug name (&/or SNOMED ID)		
d. Drug formulation		
e. Drug strength		
 f. Drug unit of measure (e.g., milligrams, micrograms, vials) 		
g. Quantity dispensed (in UOM)		
h. Quantity prescribed (in UOM)		

Please indicate yes or no per item			
Yes No			
i. Number of patients treated			

14. Do you already produce a report such as this within the Trust?

	Please tick one option
c. Yes	
d. No	

15. What is the name of this report?

Please specify		

16. Which team or department is responsible for producing this report?

Please specify			

 In September 2021 we understand that a new standard is being implemented for the Drugs Patient Level Contract Monitoring (DrPLCM) report, which is submitted monthly by every NHS Trust. Please see <u>DCB2212</u> Drugs Patient Level Contract Monitoring (DrPLCM) Version 2.0 released 8th April 2021.

To what extent will your Trust be able to submit the data field named <u>'Therapeutic indication</u> <u>code (SNOMED CT)'</u>, or a description of the indication, alongside details of drug treatment, as stipulated by NHS England by the end of 2021?

Please tick one option			Please tick one option
------------------------	--	--	------------------------

	Please tick one option
a. Fully	
b. Partially	
c. Not at all	

18. Which of the following diagnoses or indications are detailed in the latest DrPLCM report for your Trust?

We are interested in the level of detail (e.g., medical oncology versus ovarian cancer) as well as the specific diagnoses.

Please indicate yes or no for each diagnosis description			
Diagnosis description	Yes	No	
Immunology		Ø	
Atopic dermatitis			
Crohn's disease		Ø	
Plaque psoriasis		Ø	
Rheumatoid arthritis		Ø	
Severe asthma		Image: Second se	
Ulcerative colitis		Ø	
Multiple sclerosis		Ø	
Primary progressive multiple sclerosis		Ø	
Relapsing remitting multiple sclerosis		Ø	
Ophthalmology		Ø	
Wet age-related macular degeneration		Ø	
Dry age-related macular degeneration		Ø	
Diabetic macular oedema		Ø	
Medical oncology		Ø	
Breast cancer		Ø	

Please indicate yes or no for each diagnosis description		
Diagnosis description	Yes	No
Lung cancer		
NSCLC		
SCLC		
Melanoma		
Ovarian cancer		
Prostate cancer		
Renal carcinoma		
Haematology		
Non Hodgkin Lymphoma		
Hodgkin's Disease		
Acute Myeloid Leukaemia		
Chronic Lymphocytic Leukaemia		
Multiple Myeloma		M